Stanley Cohen1, Piotr A Klimiuk2, Tillmann Krahnke3, Deepak Assudani4. 1. a Metroplex Clinical Research Center , Dallas , USA. 2. b Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny , Bialystok , Poland. 3. c Cogitars GmbH , Heidelberg , Germany. 4. d Boehringer Ingelheim , Ingelheim a.R. , Germany.
Abstract
BACKGROUND: This study examined the patient handling experience and self-injection success of patients with rheumatoid arthritis (RA) administering BI 695501 using an AI. METHODS: This Phase II, 7-week, open-label, interventional study (NCT02636907) included adult patients with moderately to severely active RA not adequately controlled by DMARDs, with no experience of self-injecting with AI/pen. Patients self-injected BI 695501 via AI every 2 weeks in the AI Assessment Period (AAP). Training was given on first injection; AI handling events were recorded. Percentage of self-injection success was the primary end point. Patients could enter a 42-week pre-filled syringe (PFS) safety extension. RESULTS: The AAP was completed by 73/77 patients. In total, 216/218 (99.1%) self-injections on Days 15, 29, and 43, were successful. Nine (11.7%) patients had drug-related adverse events (AEs). Two patients reported four serious AEs (SAEs), none drug-related. Overall (in the AAP and PFS extension), 28 (36.4%) patients had drug-related AEs; nine patients had SAEs, one was considered drug-related. Five (6.5%) patients reported injection-site reactions in the AAP; 13 (18.1%) in the PFS extension. CONCLUSIONS: After training, almost all patients were successfully able to self-administer BI 695501 using an AI. BI 695501 via AI (and via PFS in the extension) was well tolerated. CLINICAL TRIAL REGISTRATION: NCT02636907.
BACKGROUND: This study examined the patient handling experience and self-injection success of patients with rheumatoid arthritis (RA) administering BI 695501 using an AI. METHODS: This Phase II, 7-week, open-label, interventional study (NCT02636907) included adult patients with moderately to severely active RA not adequately controlled by DMARDs, with no experience of self-injecting with AI/pen. Patients self-injected BI 695501 via AI every 2 weeks in the AI Assessment Period (AAP). Training was given on first injection; AI handling events were recorded. Percentage of self-injection success was the primary end point. Patients could enter a 42-week pre-filled syringe (PFS) safety extension. RESULTS: The AAP was completed by 73/77 patients. In total, 216/218 (99.1%) self-injections on Days 15, 29, and 43, were successful. Nine (11.7%) patients had drug-related adverse events (AEs). Two patients reported four serious AEs (SAEs), none drug-related. Overall (in the AAP and PFS extension), 28 (36.4%) patients had drug-related AEs; nine patients had SAEs, one was considered drug-related. Five (6.5%) patients reported injection-site reactions in the AAP; 13 (18.1%) in the PFS extension. CONCLUSIONS: After training, almost all patients were successfully able to self-administer BI 695501 using an AI. BI 695501 via AI (and via PFS in the extension) was well tolerated. CLINICAL TRIAL REGISTRATION: NCT02636907.
Entities:
Keywords:
Adalimumab; BI 695501; autoinjector; biosimilar; rheumatoid arthritis
Authors: Roy M Fleischmann; Amy E Bock; Wuyan Zhang; Charles M Godfrey; Ivana Vranic; Carol Cronenberger; Eva Dokoupilová Journal: Rheumatol Ther Date: 2022-03-18
Authors: Martin Schipperus; Georgia Kaiafa; Louise Taylor; Sally Wetten; Georg Kreuzbauer; Andy Boshier; Anouchka Seesaghur Journal: Drug Saf Date: 2019-01 Impact factor: 5.606
Authors: Antonia Davidson; Darin Brimhall; Jonathan Kay; Edward Keystone; Sang Joon Lee; Sung Hyun Kim; Yun Ju Bae; Eun Jin Choi; Daniel E Furst Journal: Br J Clin Pharmacol Date: 2021-05-09 Impact factor: 4.335